Skip to content
Ritrattodellasalute· @ritrattosalute · X·· 3 days agoScore70

NATALEE

Body · original

Ad #ESMO26 novità per il trattamento di alcune forme di #tumorealseno dai risultati dell'analisi di follow-up a 6 anni dello studio NATALEE.

L'articolo: https://www.medinews.it/comunicati/ribociclib-dimostra-un-beneficio-in-termini-di-sopravvivenza-globale-nella-piu-ampia-popolazione-di-pazienti-con-tumore-della-mammella-hr-her2%e2%88%92-in-fase-iniziale/

@myESMO

53 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

Source: Ritrattodellasalute · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.